Monthly sulfadoxine/pyrimethamine-amodiaquine or dihydroartemisinin-piperaquine as malaria chemoprevention in young Kenyan children with sickle cell anemia: A randomized controlled trial
ConclusionsIn this study with limited malaria transmission, malaria chemoprevention in Kenyan children with SCA with monthly SP-AQ or DP did not reduce clinical malaria, but DP was associated with reduced dactylitis andP.falciparum parasitization. Pragmatic studies of chemoprevention in higher malaria transmission settings are warranted. Trial registrationclinicaltrials.gov (NCT03178643).Pan-African Clinical Trials Registry: PACTR201707002371165.
Source: PLoS Medicine - Category: Internal Medicine Authors: Steve M. Taylor Source Type: research
More News: African Health | Anemia | Boys | Children | Clinical Trials | Endemics | Hematology | Internal Medicine | Kenya Health | Malaria | Parasitology | Sickle Cell Anemia | Statistics | Study